Je možná prevence ovariálního karcinomu?

Stáhnout PDF English version

Autoři: Ali Tariq Aus
Působiště autorů: Department of Chemical Pathology, NHLS, Tygerberg Hospital and Stellenbosch Faculty of Medicine  and Health Sciences, Cape Town, South Africa
Vyšlo v časopise: Ceska Gynekol 2020; 85(1): 49-58
Kategorie: Přehledový článek

Souhrn

Úvod: Program na prevenci ovariálního karcinomu by měl podporovat všechny metody snižující riziko jejího rozvoje. Patří sem metody konzervativní a chirurgické. Mezi konzervativní způsoby řadíme perorální kontraceptiva, multiparitu a kojení. Důležité jsou i takové metody, které snižují zánět a oxidační stres jako například pravidelné cvičení a zdravá strava. Mezi chirurgické metody řadíme ligaci vejcovodů, hysterektomii a profylaktickou bilaterální adnexetomii.

Cíl práce: Zdůraznit protektivní faktory v prevenci karcinomu ovarií s cílem zvýšit povědomí žen a zjistit, zda jsou tyhle způsoby jako prevence dostačující.

Metody: Přehledový článek.

Název a sídlo pracoviště: Department of Chemical Pathology, NHLS, Tygerberg Hospital and Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town.

Metodika: Literární zdroje byly vyhledávány pomocí PubMed a Google vyhledávače.

Závěr: Ovariální karcinom není kompletně preventabilní onemocnění, nicméně zavádění preventivních způsobů do praxe významně snižuje jejich incidenci. Multiparita a delší doba kojení je nejvíce zdůrazňovaným přístupem, i když není úplně možný u všech žen. Hysterektomie a ligace vejcovodů taky signifikantně snižují riziko karcinomu. Salpingektomie může poskytovat prevenci pro ženy se středním rizikem, u žen s vysokým rizikem (mutace BRCA a pozitivní rodinná anamnéza) je doporučována adnexektomie. Zdůrazňování všech těchto metod může snižovat riziko a incidenci karcinomu ovarii a potenciálně zvyšovat pětileté přežití pacientek.

Klíčová slova:

karcinom ovarii – kontraceptiva – aspirin – parita – kojení – fyzická aktivita – profylaktický chirurgický zákrok

Zdroje

1. Baandrup, L., Faber, MT., Christensen, J., et al. Nonsteroidal anti-inflammatory drugs and risk of ovarian cancer: systematic review and meta-analysis of observational studies. Acta Obstet Gynecol Scand, 2013, 92(3), p. 245–255.

2. Baandrup, L., Kjaer, SK., Olsen, JH., et al. Low-dose aspirin use and the risk of ovarian cancer in Denmark. Ann Oncol, 2015, 26, p. 787–792.

3. Bhaskaran, K., Douglas, I., Forbes, H., et al. Body-mass index and risk of 22 specific cancers: a population-based cohort study of 5·24 million UK adults. Lancet, 2014, 384(9945), p. 755–765.

4. Blank, MM., Wentzensen, N, Murphy, MA., et al. Dietary fat intake and risk of ovarian cancer in the NIH-AARP Diet and Health Study. Br J Cancer., 2012, 106(3), p. 596–602.

5. Bober, SL., Recklitis, CJ., Bakan, J., et al. Addressing sexual dysfunction after risk-reducing salpingooophorectomy: effects of a brief, psychosexual intervention. J Sexual Med, 2015, 12(1), p. 189–197.

6. Boyle, P., Maisonneuve, P., Autier, P. Update on cancer control in women. Int J Gynaecol Obstet, 2000, 70, p. 263–303.

7. Calder, PC., Ahluwalia, N., Brouns, F., et al. Dietary factors and low-grade inflammation in relation to overweight and obesity. Br J Nutr, 2011, 106(Suppl. 3), p. S5–78.

8. Cannioto, RA., LaMonte, MJ., Kelemen, LE., et al. Recreational physical inactivity and mortality in women with invasive epithelial ovarian cancer: evidence from the Ovarian Cancer Association Consortium. Br J Cancer, 2016, 115(1), p. 95–101.

9. Cannioto, R., LaMonte, MJ., Risch, HA., et al. Chronic recreational physical inactivity and ovarian cancer risk: Evidence from the Ovarian Cancer Association Consortium. Cancer Epidemiol Biomarkers Prev, 2016, 25(7), p. 1114–1124.

10. Chen, Y., Du, H., Bao, L., Liu, W. Opportunistic salpingectomy at benign gynecological surgery for reducing ovarian cancer risk: a 10-year single centre experience from China and a literature review. J Cancer, 2018, 9(1), p. 141–147.

11. Cibula, D., Widschwendter, M., Májek, O., Dusek, L. Tubal ligation and the risk of ovarian cancer: review and meta-analysis. Hum Reprod Update, 2011, 17(1), p. 55–67.

12. Cibula, D., Zikan, M., Dusek, L., Majek, O. Oral contraceptives and risk of ovarian and breast cancers in BRCA mutation carriers: a meta-analysis. Expert Rev, Anticancer Ther, 2011, 11(8), p. 1197–1207.

13. Cress, RD., Chen, YS., Morris, CR., et al. Characteristics of long-term survivors of epithelial ovarian cancer. Obstet Gynecol, 2015, 126(3), p. 491–497.

14. Dilley, SE., Havrilesky, LJ., Bakkum-Gamez, J., et al. Cost-effectiveness of opportunistic salpingectomy for ovarian cancer prevention. Gynecol Oncol, 2017, 146(2), p. 373–379.

15. Falconer, H., Yin, L., Grönberg, H., Altman, D. Ovarian cancer risk after salpingectomy: a nationwide population-based study. J Natl Cancer Inst, 2015, 107(2).

16. Finch, A., Beiner, M., Lubinski, J., et al. Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 mutation. JAMA, 2006, 296(2), p. 185–192.

17. Friebel, TM., Domchek, SM., Rebbeck, TR. Modifiers of cancer risk in BRCA1 and BRCA2 mutation carriers: systematic review and meta-analysis. J Natl Cancer Inst, 2014, 106(6), dju091.

18. Gaitskell, K., Coffey, K., Green, J., et al. Tubal ligation and incidence of 26 site-specific cancers in the Million Women Study. Br J Cancer, 2016, 114(9), p. 1033–1037.

19. Gierisch, JM., Coeytaux, RR., Urrutia, RP., et al. Oral contraceptive use and risk of breast, cervical, colorectal, and endometrial cancers: a systematic review. Cancer Epidemiol Biomarkers Prev, 2013, 22(11), p. 1931–1943.

20. Grabrick, DM., Hartmann, LC., Cerhan, JR., et al. Risk of breast cancer with oral contraceptive use in women with a family history of breast cancer. JAMA, 2000, 284(14), p. 1791–1798.

21. Greggi, S., Parazzini, F., Paratore, MP., et al. Risk factors for ovarian cancer in central Italy. Gynecol Oncol, 2000, 79(1), p. 50–54.

22. Gronwald, J., Byrski, T., Huzarski, T., et al. Influence of selected lifestyle factors on breast and ovarian cancer risk in BRCA1 mutation carriers from Poland. Breast Cancer Res Treat, 2006, 95(2), p. 105–109.

23. Grosso, G., Bella, F., Godos, J., et al. Possible role of diet in cancer: systematic review and multiple meta-analyses of dietary patterns, lifestyle factors, and cancer risk. Nutr Rev, 2017, 75(6), p. 405–419.

24. Gudkov, AV., Gurova, KV., Komarova, EA. Inflammation and p53: A tale of two stresses. Genes Cancer, 2011, 2(4), p. 503–516.

25. Guidozzi, F. Hormone therapy after prophylactic risk reducing bilateral salpingo-oophorectomy in women who have BRCA gene mutation. Climacteric, 2016, 19(5), p. 419–422.

26. Hankinson, SE., Colditz, GA., Hunter, DJ., et al. A prospective study of reproductive factors and risk of epithelial ovarian cancer. Cancer, 1995, 76(2), p. 284–290.

27. Herder, C., Peltonen, M., Koenig, W., et al. Systemic immune mediators and lifestyle changes in the prevention of type 2 diabetes: results from the Finnish Diabetes Prevention Study. Diabetes, 2006, 55(8), p. 2340–2346.

28. Hibler, EA., Kauderer, J., Greene, MH., et al. Bone loss after oophorectomy among high-risk women: an NRG oncology/gynecologic oncology group study. Menopause, 2016, 23(11), p. 1228–1232.

29. Huang, WY., Daugherty, SE., Shiels, MS., et al. Aspirin use and mortality in two contemporary U.S. cohorts. Epidemiology, 2018, 29(1), p. 126–133.

30. Huang, Y., Lichtenberger, LM., Taylor, M., et al. Antitumor and antiangiogenic effects of Aspirin-PC in ovarian cancer. Mol Cancer Ther, 2016, 15(12), p. 2894–2904.

31. Huo, X., Yao, L., Han, X., et al. Hysterectomy and risk of ovarian cancer: a systematic review and meta-analysis. Arch Gynecol Obstet, 2019, 299(3), p. 599–607.

32. Iversen, L., Fielding, S., Lidegaard, C., et al. Association between contemporary hormonal contraception and ovarian cancer in women of reproductive age in Denmark: prospective, nationwide cohort study. BMJ, 2018, 362, p. k3609.

33. Iversen, L., Sivasubramaniam, S., Lee, AJ., et al. Lifetime cancer risk and combined oral contraceptives: the Royal College of General Practitioners‘ Oral Contraception Study. Am J Obstet Gynecol, 2017, 216(6), p. 580.e1–580.e9.

34. Köbel, M., Kalloger, SE., Lee, S., et al. Ovarian Tumor Tissue Analysis consortium. Biomarker-based ovarian carcinoma typing: a histologic investigation in the ovarian tumor tissue analysis consortium. Cancer Epidemiol Biomarkers Prev, 2013, 22(10), p. 1677–1686.

35. Kolahdooz, F., Ibiebele, TI., van der Pols, JC., Webb, PM. Dietary patterns and ovarian cancer risk. Am J Clin Nutr, 2009, 89(1), p. 297–304.

36. Kolahdooz, F., van der Pols, JC., Bain, CJ., et al. Meat, fish, and ovarian cancer risk: Results from 2 Australian case-control studies, a systematic review, and meta-analysis. Am J Clin Nutr, 2010, 91(6), p. 1752–1763.

37. Kotsopoulos, J., Lubinski, J., Gronwald, J., et al. Hereditary Breast Cancer Clinical Study Group. Factors influencing ovulation and the risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers. Int J Cancer, 2015, 137(5), p. 1136–1146.

38. Li, DP., Du, C., Zhang, ZM., et al. Breastfeeding and ovarian cancer risk: a systematic review and meta-analysis of 40 epidemiological studies. Asian Pac J Cancer Prev, 2014, 15(12), p. 4829–4837.

39 Liu, Y., Warren Andersen, S., Wen, W., et al. Prospective cohort study of general and central obesity, weight change trajectory, and risk of major cancers among Chinese women. Int J Cancer, 2016, 139(7), p. 1461–1470.

40. Madsen, C., Baandrup, L., Dehlendorff, C., Kjaer, SK. Tubal ligation and salpingectomy and the risk of epithelial ovarian cancer and borderline ovarian tumors: a nationwide case-control study. Acta Obstet Gynecol Scand, 2015, 94(1), p. 86–94.

41. Marchetti, C., De Felice, F., Palaia, I., et al. Risk-reducing salpingo-oophorectomy: a meta-analysis on impact on ovarian cancer risk and all-cause mortality in BRCA 1 and BRCA 2 mutation carriers. BMC Womens Health, 2014, 14, p. 150.

42. McAlpine, JN., Tone, AA., Hanley, GE. Opportunistic salpingectomy: We chose to act, not wait. J Obstet Gynaecol Can, 2016, 38(5), p. 425–427.

43. McNamara, C., Abbott, SE., Bandera, EV., et al. Tubal ligation and ovarian cancer risk in African American women. Cancer Causes Control, 2017, 28(10), p. 1033–1041.

44. Merritt, MA., De Pari, M., Vitonis, AF., et al. Reproductive characteristics in relation to ovarian cancer risk by histologic pathways. Hum Reprod, 2013, 28(5), p. 1406–1417.

45. Milne, RL., Osorio, A., Ramón y Cajal, T., et al. Parity and the risk of breast and ovarian cancer in BRCA1 and BRCA2 mutation carriers. Breast Cancer Res Treat, 2010, 119(1), p. 221–232.

46. Nagle, CM., Dixon, SC., Jensen, A., et al. Ovarian Cancer Association Consortium. Obesity and survival among women with ovarian cancer: results from the Ovarian Cancer Association Consortium. Br J Cancer, 2015, 113(5), p. 817–826.

47. Narod, SA., Dubé, MP., Klijn, J., et al. Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst, 2002, 94(23), p. 1773–1779.

48. Narod, SA., Sun, P., Ghadirian, P., Lynch, H., et al. Tubal ligation and risk of ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study. Lancet, 2001, 357(9267), p. 1467–1470.

49. Pal, S., Bhattacharjee, A., Ali, A., et al. Chronic inflammation and cancer: potential chemoprevention through nuclear factor kappa B and p53 mutual antagonism. J Inflamm (Lond), 2014, 11, p. 23.

50. Pan, SY., Ugnat, AM., Mao, Y., et al. A case-control study of diet and the risk of ovarian cancer. Cancer Epidemiol Biomarkers Prev, 2004, 13(9), p. 1521–1527.

51. Pan, SY., Ugnat, AM., Mao, Y. Physical activity and the risk of ovarian cancer: a case control study in Canada. Int J Cancer, 2005, 117(2), p. 300–307.

52. Park, B., Park, S., Shin, HR., et al. Population attributable risks of modifiable reproductive factors for breast and ovarian cancers in Korea. BMC Cancer, 2016, 16, p. 5.

53. Peres, LC., Alberg, AJ., Bandera, EV., et al. Premenopausal hysterectomy and risk of ovarian cancer in African-American women. Am J Epidemiol, 2017, 186(1), p. 46–53.

54. Peres, LC., Camacho, F., Abbott, SE., et al. Analgesic medication use and risk of epithelial ovarian cancer in African American women. Brit J Cancer, 2016, 114, p. 819–825.

55. Purdie, DM., Bain, CJ., Siskind, V., et al. Hormone replacement therapy and risk of epithelial ovarian cancer. Br J Cancer, 1999, 81(3), p. 559–563.

56. Qiu, W., Lu, H., Qi, Y., Wang, X. Dietary fat intake and ovarian cancer risk: a meta-analysis of epidemiological studies. Oncotarget, 2016, 7(24), p. 37390–37406.

57. Rebbeck, TR., Kauff, ND., Domchek, SM. Meta-analysis of risk reduction estimates associated with risk reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers. J Natl Cancer Inst, 2009, 101, p. 80–87.

58. Rice, MS., Murphy, MA., Vitonis, AF., et al. Tubal ligation, hysterectomy and epithelial ovarian cancer in the New England Case-Control Study. Int J Cancer, 2013, 133(10), p. 2415–2421.

59. Rice, MS., Hankinson, SE., Tworoger, SS. Tubal ligation, hysterectomy, unilateral oophorectomy, and risk of ovarian cancer in the Nurses‘ Health Studies. Fertil Steril, 2014, 102(1), p. 192–198.e3.

60. Riman, T., Dickman, PW., Nilsson, S., et al. Some life-style factors and the risk of invasive epithelial ovarian cancer in Swedish women. Eur J Epidemiol, 2004, 19(11), p. 1011–1019.

61. Rodriguez, C., Calle, EE., Fakhrabadi-Shokoohi, D., et al. Body mass index, height, and the risk of ovarian cancer mortality in a prospective cohort of postmenopausal women. Cancer Epidemiol Biomarkers Prev, 2002, 11(9), p. 822–828.

62. Siegel, R., Ma, J., Zou, Z., Jemal, A. Cancer statistics, 2014. CA Cancer J Clin, 2014, 64(1), p. 9–29.

63. Sieh, W., Salvador, S., McGuire, V., et al. Tubal ligation and risk of ovarian cancer subtypes: a pooled analysis of case-control studies. Int J Epidemiol, 2013, 42(2), p. 579–589.

64. Sung, HK., Ma, SH., Choi, JY., et al. The effect of breastfeeding duration and parity on the risk of epithelial ovarian cancer. A systemic review and meta-analysis. J Prev Med Public Health, 2016, 49(6), p. 349–366.

65. Tabung, FK., Huang, T., Giovannucci, EL., et al. The inflammatory potential of diet and ovarian cancer risk: results from two prospective cohort studies. Br J Cancer, 2017, 117(6), p. 907–911.

66. Tavani, A., Gallus, S., La Vecchia, C., et al. Physical activity and risk of ovarian cancer: an Italian case-control study. Int J Cancer, 2001, 91, p. 407–411.

67. Tinelli, A., Malvasi, A., Leo, G., et al. Hereditary ovarian cancers: from BRCA mutations to clinical management. A modern appraisal. Cancer Metastasis Rev, 2010, 29(2), p. 339–350.

68. Trabert, B., Ness, RB., Lo-Ciganic, WH., et al. Ovarian Cancer Association Consortium. Aspirin, nonaspirin nonsteroidal anti-inflammatory drug, and acetaminophen use and risk of invasive epithelial ovarian cancer: a pooled analysis in the Ovarian Cancer Association Consortium. J Natl Cancer Inst, 2014, 106(2), djt431.

69. Tzonou, A., Hsieh, CC., Polychronopoulou, A., et al. Diet and ovarian cancer: a case-control study in Greece. Int J Cancer, 1993, 55(3), 4, p. 11–414.

70. Vachon, CM., Mink, PJ., Janney, CA., et al. Association of parity and ovarian cancer risk by family history of breast or ovarian cancer in a population-based study of postmenopausal women. Epidemiology, 2002, 13(1), p. 66–71.

71. Vaughan, LE., Prizment, A., Blair, CK., et al. Aspirin use and the incidence of breast, colon, ovarian, and pancreatic cancers in elderly women in the Iowa Women‘s Health Study. Cancer Causes Control, 2016, 27(11), p. 1395–1402.

72. Victora, CG., Bahl, R., Barros, AJ., et al. Breastfeeding in the 21st century: epidemiology, mechanisms, and lifelong effect. Lancet, 2016, 387(10017), p. 475–490.

73. Whiteman, MK., Hillis, SD., Jamieson, DJ., et al. Inpatient hysterectomy surveillance in the United States, 2000–2004. Am J Obstet Gynecol, 2008, 198(1), 34.e1–7.

74. Xia, L., Tan, S., Zhou, Y., et al. Role of the NFκB-signaling pathway in cancer. Onco Targets Ther, 2018, 11, p. 2063–2073.

75. Yoon, SH., Kim, SN., Shim, SH., et al. Bilateral salpingectomy can reduce the risk of ovarian cancer in the general population: A meta-analysis. Eur J Cancer, 2016, 55, p. 38–46.

76. Yuhara, H., Corley, DA., Nakahara, F., et al. Aspirin and non-aspirin NSAIDs increase risk of colonic diverticular bleeding: a systematic review and meta-analysis. J Gastroenterol, 2014, 49, p. 992–1000.

77. Zhang, D., Bai, B., Xi, Y., et al. Is aspirin use associated with a decreased risk of ovarian cancer? A systematic review and meta-analysis of observational studies with dose-response analysis. Gynecol Oncol, 2016, 142(2), p. 368–377.

78. Zhang, M., Holman, CD., Binns, CW. Intake of specific carotenoids and the risk of epithelial ovarian cancer. Br J Nutr, 2007, 98(1), p. 187–193.

79. Zhang, M., Lee, AH., Binns, CW. Physical activity and epithelial ovarian cancer risk: a case-control study in China. Int J Cancer, 2003, 105(6), p. 838–843.

80. Zhang, M., Lee, AH., Binns, CW. Reproductive and dietary risk factors for epithelial ovarian cancer in China. Gynecol Oncol, 2004, 92(1), p. 320–326.

81. Zhang, M., Yang, ZY., Binns, CW., Lee, AH. Diet and ovarian cancer risk: a case-control study in China. Br J Cancer, 2002, 86(5), p. 712–717.